Literature DB >> 11099990

Rate-control versus conversion strategy in postoperative atrial fibrillation: a prospective, randomized pilot study.

J K Lee1, G J Klein, A D Krahn, R Yee, K Zarnke, C Simpson, A Skanes, B Spindler.   

Abstract

BACKGROUND: Atrial fibrillation remains a frequent complication after heart surgery. The optimal strategy to treat the condition has not been established. Several retrospective studies have suggested that a primary rate-control strategy may be equivalent to a strategy that restores sinus rhythm.
METHODS: Fifty patients with atrial fibrillation after heart surgery were randomly assigned to a strategy of antiarrhythmic therapy with or without electrical cardioversion or ventricular rate control. Both arms received anticoagulation with heparin overlapped with warfarin. The primary end point was time to conversion to sinus rhythm analyzed by the Kaplan-Meier method. Atrial fibrillation relapse after the initial conversion was monitored in the hospital over a 2-month period.
RESULTS: There was no significant difference between an antiarrhythmic conversion strategy (n = 27) and a rate-control strategy (n = 23) in time to conversion to sinus rhythm (11.2 +/- 3. 2 vs 11.8 +/- 3.9 hours; P =.8). With the use of Cox multivariate analysis to control for the effects of age, sex, beta-blocker usage, and type of surgery, the antiarrhythmic strategy showed a trend toward reducing the time from treatment to restoration of sinus rhythm (P =.08). The length of hospital stay was reduced in the antiarrhythmic arm compared with the rate-control strategy (9.0 +/- 0.7 vs 13.2 +/- 2.0 days; P =.05). In-hospital relapse rates in the antiarrhythmic arm were 30% compared with 57% in the rate-control strategy (P =.24). There were no significant difference in relapse rates at 1 week (24% vs 28%), 4 weeks (6% vs 12%), and 6 to 8 weeks (4% vs 9%). At the end of the study, 91% of the patients in the rate-control arm were in sinus rhythm compared with 96% in the antiarrhythmic arm (P =.6).
CONCLUSIONS: This pilot study shows little difference between a rate-control strategy and a strategy to restore sinus rhythm. Regardless of strategy, most patients will be in sinus rhythm after 2 months. A larger randomized, controlled study is needed to assess the impact of restoration of sinus rhythm on length of stay.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11099990     DOI: 10.1067/mhj.2000.111104

Source DB:  PubMed          Journal:  Am Heart J        ISSN: 0002-8703            Impact factor:   4.749


  15 in total

1.  Patterns of atrial fibrillation after coronary artery bypass surgery.

Authors:  Jacqueline E Tamis-Holland; Marcin Kowalski; Velisar Rill; Kamran Firoozi; Jonathan S Steinberg
Journal:  Ann Noninvasive Electrocardiol       Date:  2006-04       Impact factor: 1.468

2.  Variation in management of post-operative atrial fibrillation (POAF) after thoracic surgery.

Authors:  Heidi Oi-Yee Li; Heather A Smith; Olivier Brandts-Longtin; Donna E Maziak; Sebastien Gilbert; Paul Villeneuve; Sudhir Sundaresan; Andrew J E Seely
Journal:  Gen Thorac Cardiovasc Surg       Date:  2021-01-05

Review 3.  2014 AATS guidelines for the prevention and management of perioperative atrial fibrillation and flutter for thoracic surgical procedures.

Authors:  Gyorgy Frendl; Alissa C Sodickson; Mina K Chung; Albert L Waldo; Bernard J Gersh; James E Tisdale; Hugh Calkins; Sary Aranki; Tsuyoshi Kaneko; Stephen Cassivi; Sidney C Smith; Dawood Darbar; Jon O Wee; Thomas K Waddell; David Amar; Dale Adler
Journal:  J Thorac Cardiovasc Surg       Date:  2014-06-30       Impact factor: 5.209

Review 4.  Should rhythm control be preferred in younger atrial fibrillation patients?

Authors:  Shaojie Chen; Yuehui Yin; Mitchell W Krucoff
Journal:  J Interv Card Electrophysiol       Date:  2012-05-22       Impact factor: 1.900

5.  Incidence, Predictors, and Impact of Postoperative Atrial Fibrillation after Coronary Artery Bypass Grafting in Military Veterans.

Authors:  Shuab Omer; Lorraine D Cornwell; Ankur Bakshi; Eric Rachlin; Ourania Preventza; Todd K Rosengart; Joseph S Coselli; Scott A LeMaire; Nancy J Petersen; Greg Pattakos; Faisal G Bakaeen
Journal:  Tex Heart Inst J       Date:  2016-10-01

6.  A Wolf in Sheep's Skin? Postoperative Atrial Fibrillation After Cardiac Surgery and the Risk of Stroke and Mortality.

Authors:  Sergey Karamnov; Benjamin O'Brien; Jochen D Muehlschlegel
Journal:  J Cardiothorac Vasc Anesth       Date:  2021-08-20       Impact factor: 2.894

Review 7.  Prophylaxis and management of postoperative atrial fibrillation.

Authors:  Orhan Onalan; Ilan Lashevsky; Eugene Crystal
Journal:  Curr Cardiol Rep       Date:  2005-09       Impact factor: 2.931

8.  Rate Control versus Rhythm Control for Atrial Fibrillation after Cardiac Surgery.

Authors:  A Marc Gillinov; Emilia Bagiella; Alan J Moskowitz; Jesse M Raiten; Mark A Groh; Michael E Bowdish; Gorav Ailawadi; Katherine A Kirkwood; Louis P Perrault; Michael K Parides; Robert L Smith; John A Kern; Gladys Dussault; Amy E Hackmann; Neal O Jeffries; Marissa A Miller; Wendy C Taddei-Peters; Eric A Rose; Richard D Weisel; Deborah L Williams; Ralph F Mangusan; Michael Argenziano; Ellen G Moquete; Karen L O'Sullivan; Michel Pellerin; Kinjal J Shah; James S Gammie; Mary Lou Mayer; Pierre Voisine; Annetine C Gelijns; Patrick T O'Gara; Michael J Mack
Journal:  N Engl J Med       Date:  2016-04-04       Impact factor: 91.245

Review 9.  Postoperative Atrial Fibrillation Following Cardiac Surgery: From Pathogenesis to Potential Therapies.

Authors:  Yousef Rezaei; Mohammad Mehdi Peighambari; Shayan Naghshbandi; Niloufar Samiei; Alireza Alizadeh Ghavidel; Mohammad Reza Dehghani; Majid Haghjoo; Saeid Hosseini
Journal:  Am J Cardiovasc Drugs       Date:  2020-02       Impact factor: 3.571

Review 10.  Postoperative arrhythmias after cardiac surgery: incidence, risk factors, and therapeutic management.

Authors:  Giovanni Peretto; Alessandro Durante; Luca Rosario Limite; Domenico Cianflone
Journal:  Cardiol Res Pract       Date:  2014-01-06       Impact factor: 1.866

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.